Get the Stockscreener App
0.9783
2.90%
0.0276
After Hours:
.99
0.0117
+1.20%
Alzamend Neuro Inc Stock (ALZN) Latest News
Alzamend Neuro director William B. Horne purchases $4,891 in shares - Investing.com
Alzamend Neuro director William B. Horne purchases $4,891 in shares By Investing.com - Investing.com UK
Alzamend Neuro director William B. Horne buys $4,851 in stock By Investing.com - Investing.com South Africa
Alzamend Neuro director William B. Horne buys $4,851 in stock - Investing.com
Alzamend Neuro director Milton C. Ault III acquires $4,810 in shares - Investing.com
Alzamend Neuro, Inc. Plans Phase II Clinical Study of AL001 in Major Depressive Disorder to Compare Lithium Delivery with Marketed Products - Nasdaq
Alzamend Neuro Announces Initiation Date of Phase II - GlobeNewswire
Major Depression Breakthrough: New Lithium Treatment Heads to Phase II at Top Hospital - StockTitan
Alzamend Neuro (ALZN) Projected to Post Earnings on Monday - Defense World
Alzamend Neuro director Milton Ault buys $68 in stock By Investing.com - Investing.com South Africa
Alzamend Neuro director Milton Ault buys $68 in stock - Investing.com
Short Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Rises By 332.2% - Defense World
Alzamend Neuro stock hits 52-week low at $0.68 amid sharp decline - Investing.com Australia
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital - BioSpace
Alzamend Neuro stock hits 52-week low at $0.68 amid sharp decline By Investing.com - Investing.com South Africa
Alzamend Neuro plans mid-stage study of its therapy for PTSD in fourth-quarter 2025 - Marketscreener.com
Major PTSD Breakthrough: New Lithium Treatment Heads to Phase II Trial at Top Hospital - StockTitan
EXCLUSIVE: Alzamend Neuro To Launch Phase 2 Study For Lead Drug For PTSD Patients In Late 2025 To Assess Lithium Delivery Benefits - Benzinga
Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Down 33.0% in February - Defense World
Alzamend Neuro Announces Initiation Date Of Phase II Clinical Trial Of AL001 For Treatment Of Bipolar Disorder To Take Place At Massachusetts General Hospital - Marketscreener.com
Alzamend Neuro announces initiation date of Phase II trial of AL001 - TipRanks
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital - The Manila Times
Alzamend Neuro Announces Phase II Clinical Study of AL001 for Bipolar Disorder Expected to Start in Q3 2025 - Nasdaq
Alzamend Neuro Plans Phase II Trial for Advanced Lithium Treatment in Bipolar Disorder | ALZN Stock News - StockTitan
Alzamend Neuro Announces Bylaws Amendment and New Stock Series By Investing.com - Investing.com South Africa
Alzamend Neuro Announces Bylaws Amendment and New Stock Series - Investing.com
Alzamend Neuro stock hits 52-week low at $0.81 amid sharp decline - Investing.com Australia
Alzamend Neuro inks deal for equity securities sale By Investing.com - Investing.com South Africa
Alzamend Neuro inks deal for equity securities sale - Investing.com
Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital - The Manila Times
Can Alzamend's New Lithium Formulation Eliminate Monitoring Requirements? Phase II Trial Set for 2025 - StockTitan
EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025 - Yahoo Finance UK
EXCLUSIVE: Alzamend Neuro Says Tesla Dynamic Completes Head Coil To Measure Brain Structure Lithium Levels - AOL
Alzamend Neuro stock hits 52-week low at $1.05 amid challenges - Investing.com
Alzamend Neuro Announces Completion Of A Novel Head Coil By Tesla For Measuring Brain Structure Lithium Levels In Five Upcoming Phase Ii Clinical Trials At Massachusetts General Hospital - Marketscreener.com
Alzamend Neuro stock hits 52-week low at $1.05 amid challenges By Investing.com - Investing.com South Africa
Alzamend Neuro announces head coil for lithium studies By Investing.com - Investing.com South Africa
Alzamend Neuro announces head coil for lithium studies - Investing.com India
ALZNAlzamend Neuro Inc Latest Stock News & Market Updates - StockTitan
Alzamend Neuro announces completion of head coil by Tesla Dynamic Coils - TipRanks
Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital - Business Wire
Alzamend Neuro stock hits 52-week low at $1.05 amid sharp decline - Investing.com Canada
Crude Oil Down 2%; Alzamend Neuro Shares Spike Higher - MSN
Short Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Grows By 130.7% - Armenian Reporter
Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Update - Defense World
Has Alzamend Neuro (ALZN) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Alzamend Neuro to Present at the Sequire Investor Summit - Business Wire
0.22%
0.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):